Recent advances in breast cancer biology

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 499-504

  DeMichele, Angela ^a   Weber, Barbara L ^a  

^a Stellar Chance Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; PROTEIN P53;

BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; GENE FUNCTION; GENETIC SUSCEPTIBILITY; GROWTH REGULATION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0030810018     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00002     Document Type: Review

References (45)

1. Sherr C: Cancer Cell Cycles. Science 1996, 274:1672-1677. An excellent review of the cell cycle.
2. Elledge S: Cell cycle checkpoints: Preventing an identity crisis. Science 1996, 274:1664-1671.
3. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, et al.: p21waf1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, Mib1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996, 74:208-15.
4. Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE: p53-independent apoptosis during mammary tumor progression in C3(1)/Sv40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 1996, 56:2998-3003.
5. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, Dalla Palma P, Bevilacqua G, Marchetti A: Cyclin-D1 -gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and P21WAF1 immunohistochemical expression. Int J Cancer 1997, 74:171-174.
6. Benson J, Baum M, Colletta A: Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br J Cancer 1996, 74:352-358.
7. MacCallum J, Keen J, Bartlett J, Thompson A, Dixon J, Miller W: Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 1996, 74:474-478.
8. Kastan M: Molecular biology of cancer: the cell cycle. In Cancer: Principles and Practice of Oncology, edn. 5. Edited by DeVita VT HS, Rosenberg S. Philadelphia: JB Lippincott, 1997:121-134.
9. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993, 85:965-970.
10. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ: Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 1996, 69:135-141.
11. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. Journal of Clinical Oncology 1996, 14:1604-1610. Looks at p53 mutations and outcome in context of other prognostic variables.
12. Lowe SW BS, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
13. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814.
14. Borresen A: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995, 14:71-75.
15. Makris A, Powles TJ, Dowsett M, Allred C: p53 protein overexpression and chemosensitivity in breast cancer(letter). Lancet 1995, 345:1181-1182.
16. Mathieu M-C, Koscielny S, Le Bihan M-L, Spielmann M, Arriagada R: p53 protein overexpression and chemosensitivity in breast cancer (letter). Lancet 1995, 345:1182.
17. Ogretmen B, Safa AR: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997, 14:499-506. Studies look at the mechanism of the interaction between p53 mutations and multidrug resistance.
18. Menard S, Casalini P, Pilotti S, Cascinelli N, Rilke F, Colnaghi MI: No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinomas [letter]. Journal of the National Cancer Institute 1996, 88:1002-1003.
19. Barbati A, Cosmi EV, Sidoni A, Collini P, Porpora MG, Ferri I, Luthy M, Lauro V, Bucciarelli E: Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Research 1997, 17:401-405. Examines the significance of concommitant p53 and c-erbB2 overexpression.
20. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, HP K: p27/kip1 mutation found in breast cancer. Cancer Research 1996, 56:2400-2404. First report of p27 alteration in breast cancer.
21. kip1 levels as a prognostic marker in breast cancer.
22. kip1 in resistance to chemotherapy.
23. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997, 57:1259-1263.
24. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997, 3:222-225.
25. Miki Y, Swensen J, Shattuck-Eidens D: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66.
26. Wooster R, Bignell G, Lancaster J: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789.
27. Easton DF, Bishop DT, Ford D, Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993, 52:678-701.
28. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med 1997, 336:1401-1408. Most recent estimates of population frequencies for Ashkenazi Jews.
29. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [see comments]. N Engl J Med 1997, 336:1409-1415. Recent data on prior probability of BRCA1 mutations and attributable risk.
30. Berry DA, Parmigiani G, J S: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997, 89:227-238.
31. Smith SA, Easton DF, Evans DG, Ponder BA: Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992, 2:128-131.
32. Gudas JM, Nguyen H, Li T: Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995, 55:4561.
33. Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH: BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996, 56:3168-3172.
34. Somasundaram K, Zhang H, Zeng Y, Wu G, Peng Y, El-Deiry W, Weber B: BRCA1 inhibition of the cell cycle requires p21waf1/cip1. (in press) 1997. New information on the possible function of BRCA1 in regulating the cell cycle.
35. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275. Describes association between Rad51 and BRCA1, suggesting BRCA1 may play a role in DNA damage surveillance and repair.
36. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386:804-810.
37. Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX: Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res 1996, 56:1457-1465.
38. Li W, Park JW, Nuijens A, Sliwkowski MX, Keller GA: Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. Oncogene 1996, 12:2473-2477.
39. BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene 1997, 14:2863-2869.
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
41. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996, 56:3350-3358. Puts into perspective the EGFR and hormone receptor pathways.
42. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, et al.: Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996, 12:2535-2547.
43. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 1996, 38:57-66. Good review of the function of heregulin in the signaling pathway and its possible role in drug resistance.
44. Groner B, Wick B, Jeschke M, Fiebig HH, Dengler W, Runau T, Mihatsch M, Kahl R, Schmidt M, Wels W, Stocklin E: Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects. Int J Cancer 1997, 70:682-687.
45. Siegall CB: Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Recent Results Cancer Res 1996, 140:51-60.